Goldman Sachs Reiterates Buy Rating on Edwards Lifesciences (EW)

Citi Removes Two names from 90-Day Catalyst Watch Lists

October 31, 2024 4:06 PM EDT

Citi Removes Two names from 90-Day Catalyst Watch Lists

Tandem Diabetes (NASDAQ: TNDM) Removed from 90-Day Downside Catalyst Watch List: "With our 3Q24 Preview (10/1/24), we opened a 90-day Negative Catalyst Watch on TNDM. The thesis was: 1) survey results suggested ~flat Tandem share of new patient starts in the U.S. in the 3Q24E; 2) while Mobi prescriptions were increasing, it... More

BofA Securities Reiterates Neutral Rating on Edwards Lifesciences (EW)

October 30, 2024 4:03 PM EDT

BofA Securities analyst Travis Steed reiterated a Neutral rating and $75.00 price target on Edwards Lifesciences (NYSE: EW).

The analyst comments "On Wednesday EW hosted a TMTT investor event after Evoque pivotal data were presented. See TRISCEND II at TCT report for our initial take on the data. We go over the key... More

Edwards Lifesciences (EW): TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-life Benefits With Edwards EVOQUE System for Severe Tricuspid Regurgitation

October 30, 2024 11:01 AM EDT

Edwards Lifesciences Corporation (NYSE: EW) today announced that the EVOQUE system demonstrated superiority compared to medical therapy alone for the one-year primary endpoint of the TRISCEND II trial. TRISCEND II is a randomized controlled pivotal trial designed to study the groundbreaking EVOQUE transcatheter tricuspid valve replacement (TTVR) system with optimal medical therapy (OMT) compared to OMT alone with 2:1 randomization. The data, presented during the late-breaking clinical trial sessions at the Transcatheter Cardiovascular Therapeutics (TCT) meeting, included the full cohort of 400 patients. TRISCEND II trial one-year primary endpoint outcomes will be simultaneously published in... More

TD Cowen Reiterates Hold Rating on Edwards Lifesciences (EW)

October 28, 2024 2:20 PM EDT

TD Cowen analyst Joshua Jennings reiterated a Hold rating and $70.00 price target on Edwards Lifesciences (NYSE: EW).

The analyst commented, "The full cohort of Triscend II will be presented as a late breaker at TCT 2024. These results could support EW's expansion of Evoque's... More

Edwards Lifesciences (EW): Groundbreaking Data Demonstrate Superiority of EARLY TAVR in Asymptomatic Severe Aortic Stenosis Patients

October 28, 2024 11:12 AM EDT

Edwards Lifesciences (NYSE: EW) today announced results from the EARLY TAVR Trial, the first randomized, controlled trial designed to study the best strategy for treating asymptomatic severe aortic stenosis (AS) and the benefits of early intervention with transcatheter aortic valve replacement (TAVR). The trial results demonstrated that asymptomatic severe AS patients randomized to Edwards TAVR experienced superior outcomes compared with guideline-recommended clinical surveillance. Trial investigators presented the data today during a late-breaking clinical trials session at Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF) and published simultaneously... More

Edwards Lifesciences (EW) Quickly Falls to Low

October 28, 2024 11:11 AM EDT

Edwards Lifesciences (NYSE: EW) Quickly Falls to Low

Shares down 3.4%
... More

Bernstein SocGen Group Upgrades Edwards Lifesciences (EW) to Market Perform

October 28, 2024 8:19 AM EDT

Bernstein SocGen Group analyst Lee Hambright upgraded Edwards Lifesciences (NYSE: EW) from to Market Perform.

The analyst comments "Our previous Underperform call on EW was based on the view that the TAVR market was experiencing slowing growth and increased competition. Now as... More

Edwards Lifesciences (EW) PT Raised to $85 at Barclays

October 28, 2024 6:12 AM EDT

Barclays analyst Matt Miksic raised the price target on Edwards Lifesciences (NYSE: EW) to $85.00 (from $80.00) while maintaining a Overweight rating.... More